Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead bifunctional antibody, ficerafusp alfa, for solid tumors. Company announcements frequently highlight progress in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative disease, and provide updates on related clinical trials and regulatory interactions.
Recent news has included updates on the pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa in combination with pembrolizumab in first-line HPV-negative R/M HNSCC, preliminary and expanded Phase 1/1b cohort data, and the selection of dosing strategies intended to inform the pivotal study. Bicara has also reported that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in a defined subset of R/M HNSCC patients, and has used press releases to discuss how clinical data supported this designation.
In addition to clinical milestones, BCAX news items cover quarterly financial results, research and development spending, and cash and investment balances, reflecting the company’s status as a clinical-stage public issuer. Bicara also issues releases about participation in major medical and investor conferences, such as oncology congresses and healthcare investment events, where it presents clinical data or engages with the investment community.
Investors and observers following BCAX news can expect updates on FORTIFI-HN01 enrollment and interim analyses, data readouts from Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer, regulatory designations and guidance, and broader corporate developments. This news page aggregates those disclosures to help readers track the evolving clinical and corporate narrative around ficerafusp alfa and Bicara’s broader solid tumor strategy.
Bicara Therapeutics (Nasdaq: BCAX) reported Q3 2024 financial results and business updates. The company completed an upsized IPO raising $362 million in gross proceeds and maintains a strong financial position with $521 million in cash, expected to fund operations into H1 2029. The company is preparing to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa for head and neck cancer treatment. Current Phase 1/1b trial shows promising results with 64% overall response rate and 18% complete response rate. Q3 financial results show R&D expenses of $15.9 million and G&A expenses of $4.8 million, with a net loss of $17.5 million.
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Claire Mazumdar will deliver a presentation on November 19, 2024 at 9:10 a.m. ET in New York. The presentation will be accessible via live webcast on Bicara's website, with a replay available for approximately 90 days afterward.
Bicara Therapeutics (Nasdaq: BCAX) has successfully closed its initial public offering (IPO) of 20,125,000 shares of common stock at $18.00 per share, raising gross proceeds of approximately $362 million. The offering included the full exercise of the underwriters' option to purchase an additional 2,625,000 shares. Trading of Bicara's shares on the Nasdaq Global Market began on September 13, 2024, under the ticker symbol 'BCAX'.
The IPO was jointly managed by Morgan Stanley, TD Cowen, Cantor, and Stifel as bookrunners. Bicara Therapeutics, a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, will use the proceeds to advance its research and development efforts.
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, has announced the pricing of its upsized initial public offering. The company is offering 17,500,000 shares of common stock at $18.00 per share. Trading is expected to begin on the Nasdaq Global Market on September 13, 2024, under the ticker symbol 'BCAX'. The offering is set to close on September 16, 2024.
Bicara has granted underwriters a 30-day option to purchase up to an additional 2,625,000 shares. The gross proceeds are expected to be approximately $315.00 million, excluding any exercise of the underwriters' option. Morgan Stanley, TD Cowen, Cantor, and Stifel are acting as joint bookrunners for the offering.